[Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or local advanced renal cell carcinoma after nephrectomy].
作者信息
Rexer H
机构信息
Geschäftsstelle der AUO, MeckEvidence, Seestraße 11 , 17252 Schwarz, Deutschland.
出版信息
Urologe A. 2011 Apr;50(4):489-92. doi: 10.1007/s00120-011-2534-6.
PMID:21472622
Abstract
摘要
Zotero 插件